Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cell tropism and viral clearance during SARS-CoV-2 lung infection

Constantin Schwab *, Lisa Maria Domke, Fabian Rose, Ingrid Hausser, Peter Schirmacher, Thomas Longerich
Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

ARTICLE INFO

Keywords:
SARS-CoV-2 infection
COVID-19
Cellular target
Time-course
Endothelialitis

ABSTRACT

Pulmonary capillary microthrombosis has been proposed as a major pathogenetic factor driving severe COVID-19. Autopsy studies reported endothelialitis but it is under debate if it is caused by SARS-CoV-2 infection of endothelial cells. In this study, RNA in situ hybridization was used to detect viral RNA and to identify the infected cell types in lung tissue of 40 patients with fatal COVID-19. SARS-CoV-2 Spike protein-coding RNA showed a steadily decreasing signal abundance over a period of three weeks. Besides the original virus strain the variants of concern Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) could also be detected by the assay. Viral RNA was mainly detected in alveolar macrophages and pulmonary epithelial cells, while only single virus-positive endothelial cells were observed even in cases with high viral load suggesting that viral infection of endothelial cells is not a key factor for the development of pulmonary capillary microthrombosis.

1. Introduction

Since late 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic [12]. While most infected people experience a bland course with mild or no symptoms at all, some patients develop a more severe corona virus disease 2019 (COVID-19) necessitating hospitalization and in severe cases intensive care unit treatment with mechanical ventilation or extracorporeal membrane oxygenation. Especially, elder people and patients with pre-existing co-morbidities are at risk to develop an acute respiratory distress syndrome [12]. As the SARS-CoV-2 genome seems to be in a hyper-mutating state, new virus variants are frequently detected and are responsible for the numerous waves of infection still keeping the world in suspense. During the last two pandemic years, several vaccines targeting the viral Spike protein have proven efficacy. In addition, medications either targeting the viral replication or acting as immunomodulators to prevent an overwhelming immune response have shown to reduce the likelihood of a fatal disease outcome. However, patients requiring mechanical ventilation still face a high risk of mortality. Thus, there is a need for deciphering the pathophysiology of COVID-19.

Several studies reported an endotheliopathy leading to increased permeability, edema, diffuse alveolar damage, hemorrhage and thrombosis [1,14,15]. While some authors claimed the detection of viral particles in infected (kidney) endothelial cells, others questioned these results and stated that structures normally found in the cytoplasm of a cell after conventional chemical fixation may be misinterpreted as viral particles [9,26]. In particular, it is still unclear whether SARS-CoV-2-related endotheliopathy is caused by viral infection of endothelial cells or by another indirect mechanism (e.g. via a cytokine storm related to strong activation of the immune system during COVID-19). Here, we analyzed the presence of viral RNA in lung tissue of COVID-19 patients over time and identified the infected cell types by dual-color RNA in situ hybridization (RNA-ISH).

2. Material and methods

2.1. Study cohort

All COVID-19 patients being referred to the Institute of Pathology, Heidelberg University Hospital for autopic examination between March, 26th 2020 and February, 28th 2022 were registered in the COVID-19 autopsy and biomaterial registry Baden Wuerttemberg. SARS-CoV-2 infection was confirmed by reverse transcriptase polymerase chain reaction performed on nasopharyngeal swab samples.
either before or during hospitalization or prior to autopsy in all patients. From this COVID-19 repository, 40 patients were selected based on the time interval between positive SARS-CoV-2 testing and death, which covered a period of one month. These included 12 patients infected by virus variants of concern. Lung tissue from autopsy cases before the COVID19 pandemic served as negative controls. The study was approved by the ethics committee of the University of Heidelberg Faculty of Medicine (no. S-242/2020) and carried out in accordance with the Declaration of Helsinki. According to the ethics vote informed consent was not required.

2.2. Autopsies

All autopsies were performed applying a standardized protocol as described previously [13]. Tissue samples were fixed immediately after organ dissection using 4% neutral-buffered formalin. To optimize lung fixation, formalin was instilled in the trachea and the major pulmonary vessels. Lung dissection was performed after three days of fixation in a formalin-filled container of adequate size. Axial sections (slice thickness: 1 cm) were retrieved and photographically documented. Three representative tissue samples were taken from each pulmonary lobe for histological examination. Tissue samples were submitted to the tissue bank of the German Center for Infection Research.

2.3. Histology

For histological evaluation, 3-μm sections were retrieved from formalin-fixed, paraffin-embedded (FFPE) samples and stained according to standard protocols (hematoxylin and eosin, periodic acid Schiff reaction, and acid fuchs in orange G). The histological sections of the lungs were assessed by at least two pathologists (TL, CS). Histological changes were recorded in a standardized fashion as reported previously [13].

2.4. RNA in situ hybridization

RNA in situ hybridization (RNA-ISH) was performed on 5-μm thick sections of FFPE lung tissues using the RNAscope® platform according to the manufacturer's instructions (Advanced Cell Diagnostics (ACD), Newark, CA, USA). For single detection of the Spike protein coding gene a SARS-CoV-2 specific probe (RNAscope® Probe V-nCoV2019-S, ACD Cat# 848561) was used together with a single detection kit (RNAscope® 2.5 HD Reagent Kit-RED, ACD, Cat# 322350). For dual RNA-ISH the duplex detection kit (RNAscope® 2.5 HD Duplex Reagent Kit, ACD, Cat# 322430) was used combining the SARS-CoV-2 specific probe and probes for Melanoma Cell Adhesion Molecule (MCAM, RNAscope® Probe Hs-MCAM-C2, ACD Cat# 601731-C2) to detect endothelial cells, keratin 18 (KRT18, RNAscope® Probe Hs-KRT18-C2, ACD Cat# 310211-C2) to detect epithelial cells, or CD68 to detect macrophages (RNAscope® Probe Hs-CD68-C2, ACD Cat# 560591-C2). In brief, FFPE slides were deparaffinized in xylene and ethanol followed by hydrogen peroxide treatment to block endogenous peroxidase activity (RNAscope® hydrogen peroxide, ACD, Cat# 322335), incubation in target retrieval solution for 15 min (RNAscope® Target Retrieval Reagents, ACD Cat# 322000), and proteolytic digestion for 30 min as pre-incubation procedures (RNAscope® Protease Plus, ACD Cat# 322331). The slides were then transferred into a pre-warmed humidity control tray (ACD) and incubated with either a mixture of Channel 1 and Channel 2 solutions for the Duplex Assay or the SARS-CoV-2-probe only in case of single probe detection. The humidity control tray was placed in a HyBe EZ oven (ACD) for 2 h of incubation at 40 °C. The slides were then washed two times using RNAscope washing buffer and returned to the oven for another 30 min after submersion in AMP-1 reagent. Washing and amplification steps were repeated using the AMP-2 to AMP-6 reagents with alternating 15-min and 30-min incubation periods, respectively. For single probe detection, the RED solution was prepared by mixing RED-A (RNAscope® Fast Red A, ACD Cat# 320458) and RED-B (RNAscope® Fast Red B, ACD Cat# 320459) in a ratio of 60:1. For signal visualization the RED solution was incubated for 10-min, followed by counterstaining with 50% hematoxylin and 0.05% ammonia. For dual probe detection, four additional amplification steps were performed before detecting the first probe using the RED solutions as describe above.

The second probe was visualized using the GREEN solutions (GREEN A (RNAscope® GREEN A, ACD Cat# 320718) plus GREEN B (RNAscope® GREEN B, ACD Cat# 320719), ratio 50:1). Counterstaining was performed as described above for single probe detection. Each slide was examined by two pathologists (TL, CS). The overall viral load was semiquantitatively assessed by visual scoring using a four-tiered system (0 – 3): score 0 (no hybridization signal detected), score 1 (focal, isolated signals), score 2 (focal, pilled signals) or score 3 (diffuse signals). In addition, the maximum number of double positive cells/mm² was counted in all cases showing a high viral load.

3. Results

3.1. Study cohort

During the recruitment period of the study 115 clinicopathological COVID-19 autopsies were performed at our institution. For this study, 40 patients of this cohort were selected and analyzed for presence and distribution of SARS-CoV-2 Spike protein-coding RNA in lung tissue. These included 28 patients infected by the original SARS-CoV-2 strain and 12 patients infected by different variants of concern (Alpha, B.1.1.7, n = 5; Delta, B.1.617.2, n = 5; Omicron, B.1.1.529, n = 2, respectively). The patients' characteristics are detailed in Table 1. The male to female ratio was 1.5:1. Median age at death was 79 years (range: 41–95 years). The mean duration of COVID-19, from onset to symptoms to death, was 10 days (range 0–31). In particular, ten of these patients died in less than one week, another nineteen during the second week, and the last eleven later than 14 days following disease onset. The mean duration of hospitalization was 7 days (range 0–36). Histological evaluation showed the previously reported pattern of lung damage over time with diffuse alveolar damage and alveolar edema observed in the exudative stage, followed by a proliferative stage characterized by pneumocyte hyperplasia, squamous metaplasia, and desquamation, and subsequently the development of an organizing pneumonia resulting in interstitial fibrosis (Fig. 1A-C) [13]. These pulmonary changes were considered the main cause of death in 26 patients. In the remaining twelve patients, autopsies revealed either bronchopneumonia related to super-infection (n = 6), myocardial infarction (n = 3), septic shock (n = 2), decompensated heart insufficiency (n = 1), pulmonary artery embolism (n = 1), or severe iron deficiency anemia (n = 1) as the underlying cause of death.

3.2. Detection of SARS-CoV-2 variants in situ

SARS-CoV-2 viral RNA was visualized in lung tissues using a probe against the Spike protein coding RNA sequence. Positive signals were retrieved within hyaline membranes covering the alveolar spaces as well as in the cytoplasm of cells within the alveoli and the alveolar septa (Fig. 1D-I). Based on the semiquantitative assessment of the SARS-CoV-2 RNA-ISH, six cases revealed a high viral load (Fig. 1D), ten cases were characterized as intermediate (Fig. 1E), and 16 cases were classified as having a low viral load (Fig. 1F). Overall, no SARS-CoV-2 virus RNA could be detected in the lung tissue sections of eight patients. As the signal abundance varied remarkably between the individual cases (Table 1), the study cohort was categorized according to disease duration (less than one week, one to two weeks, and more than two weeks, respectively), which revealed a significant inverse association between signal abundance and duration (Spearman’s rho = −0.51, p = 0.001). In particular, the viral load was significantly reduced in cases with a disease duration more than 2 weeks compared to the other two subgroups (p < 0.05, Fig. 2A). Six patients of this cohort had received a primary
vaccination series. At least in this cohort of deceased COVID-19 patients, the viral load (as determined by semiquantitative evaluation) was not significantly different between vaccinated or non-vaccinated cases (p > 0.05, Fig. 2B).

Regarding virus variants, our diagnostic approach detected 89% (n = 16/18) of the cases infected by the original virus strain and 80% (n = 16/20) of the cases infected by the Delta (B.1.617.2) and Omicron (B.1.1.529) variants, respectively. In line with this, less viral load was between abundance of viral RNA in lung tissue and age, sex, presence of diabetes mellitus (T2DM) [13]. There was no statistical association between abundance of viral RNA in lung tissue and age, sex, presence of arterial hypertension or COPD, mechanical ventilation or COVID-19-related death (each p > 0.05), but the abundance of SARS-CoV-2 signals in lung tissue was significantly less in patients with known T2DM (p = 0.01).

### Table 1

| ID | Age | Sex | Primary vaccination completed | Duration (d) | VOC | Co-morbidities | Mechanical ventilation | Viral load (ISH) | Disease stage | Cause of death |
|----|-----|-----|--------------------------------|-------------|-----|----------------|-----------------------|-----------------|---------------|----------------|
| 1  | 41  | m   | no                             | 12          | No  | FLD            |declined              | 3               | exudative     | COVID-19       |
| 2  | 89  | f   | no                             | 10          | No  | AH, CAD        |declined              | 0               | exudative     | COVID-19       |
| 3  | 81  | m   | no                             | 15          | No  | AH, DM         |declined              | 1               | NA bronchopneumonia |
| 4  | 71  | m   | no                             | 4           | No  | AH, COPD       |declined              | 1               | exudative      | myocardial insufficiency |
| 5  | 77  | f   | no                             | 5           | No  | AH, CAD, COPD  |no                  | 2               | NA bronchopneumonia |
| 6  | 95  | m   | no                             | 5           | No  | AH, ILD        |declined              | 3               | exudative     | COVID-19       |
| 7  | 73  | f   | no                             | 10          | No  | AH, MN, RA     |declined              | 2               | proliferating COVID-19 |
| 8  | 81  | f   | no                             | 5           | No  | AH, CAD, COPD, MetS |declined | 1               | fibrosing COVID-19 |
| 9  | 89  | m   | no                             | 8           | No  | AH, COPD       |declined              | 2               | exudative     | COVID-19       |
| 10 | 78  | m   | no                             | 6           | No  | AH, CAD, COPD, MN|declined              | 2               | exudative     | COVID-19       |
| 11 | 80  | m   | no                             | 7           | No  | AH, COPD       |no                  | 2               | exudative     | COVID-19       |
| 12 | 60  | f   | no                             | 8           | No  | AH, ILD        |yes                 | 3               | proliferating COVID-19 |
| 13 | 79  | m   | no                             | 9           | No  | AH, COPD, MDS  |declined              | 2               | exudative     | COVID-19       |
| 14 | 82  | m   | no                             | 11          | No  | AH, DM         |declined              | 1               | exudative     | septic multiorganfailure |
| 15 | 78  | f   | no                             | 9           | No  | AH, DM         |yes                 | 1               | fibrosing     | septic multiorganfailure |
| 16 | 79  | f   | no                             | 10          | No  | AH, DM, COPD, M, RI |declined | 0               | fibrosing COVID-19 |
| 17 | 86  | f   | no                             | 11          | No  | AH, DM, COPD, M, RI |declined | 1               | exudative     | COVID-19       |
| 18 | 90  | f   | no                             | 11          | No  | AH, DM, M, MeS, RI |declined              | 0               | fibrosing     | COVID-19       |
| 19 | 69  | m   | no                             | 15          | B.1.1.7 | AH, DM, S |yes             | 0               | fibrosing     | Myocardial infarction |
| 20 | 66  | m   | no                             | 31          | No  | CLL, COPD      |yes                 | 1               | proliferating COVID-19 |
| 21 | 86  | m   | no                             | 8           | No  | AH, CAD, COPD, MN|declined              | 2               | proliferating COVID-19 |
| 22 | 86  | f   | no                             | 14          | No  | AH, MN         |declined              | 1               | proliferating bronchopneumonia |
| 23 | 93  | f   | no                             | 15          | No  | AH, CAD, RI    |declined              | 1               | exudative     | myocardial infarction |
| 24 | 78  | m   | no                             | 15          | No  | AH              |yes                 | 1               | fibrosing     | COVID-19       |
| 25 | 78  | m   | no                             | 16          | No  | AH              |yes                 | 0               | fibrosing     | COVID-19       |
| 26 | 65  | m   | no                             | 18          | B.1.1.7 | AH, CAD, DM, MeS |yes               | 1               | fibrosing     | myocardial infarction |
| 27 | 91  | m   | no                             | 19          | No  | AH, RI         |declined              | 0               | fibrosing     | COVID-19       |
| 28 | 61  | f   | no                             | 6           | No  | MeS            |yes                 | 0               | exudative     | COVID-19       |
| 29 | 79  | m   | no                             | 22          | No  | AH, CAD, COPD, DM |yes       | 0               | fibrosing     | COVID-19       |
| 30 | 59  | m   | no                             | 27          | No  | AH, CAD, SA    |yes                 | 1               | fibrosing     | bronchopneumonia |
| 31 | 91  | m   | yes                            | 6           | B.1.1.7 | AH, CAD, COPD, S |declined              | 2               | exudative     | COVID-19       |
| 32 | 74  | m   | no                             | 9           | B.1.1.7 | CAD, K, MN    |declined              | 3               | proliferating COVID-19 |
| 36 | 68  | f   | no                             | 12          | B.1.1.7 | AH, LC, RA    |yes                 | 2               | fibrosing     | bronchopneumonia |
| 34 | 65  | m   | yes                            | 4           | B.1.617.2 | AH, CAD, MeS, S |declined              | 2               | exudative     | COVID-19       |
| 35 | 80  | f   | yes                            | 1           | B.1.617.2 | AH, CAD, COPD, NSCLC, paraplegia |declined | 3               | exudative     | bronchopneumonia |
| 36 | 88  | m   | yes                            | 0           | B.1.617.2 | AH              |yes                 | 1               | exudative     | iron deficiency anemia |
| 37 | 74  | f   | no                             | 12          | B.1.5.29 | AH, CAD, MN, NF |yes                | 1               | exudative     | COVID-19       |
| 38 | 72  | f   | no                             | 8           | B.1.617.2 | GBM            |no                  | 3               | exudative     | COVID-19 & end-stage cancer |
| 39 | 81  | m   | yes                            | 8           | B.1.617.2 | AH, CAD        |yes                 | 1               | fibrosing     | COVID-19       |
| 40 | 87  | m   | yes                            | 12          | B.1.617.2 | AH, CAD        |yes                 | 0               | fibrosing     | Pulmonary artery embolism |

Abbreviations: AH, arterial hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DCMP, dilatative cardiomyopathy; f, female; FLD, fatty liver disease; GBM, glioblastoma multiforme; ILD, interstitial lung disease; K, kyphoscoliosis; LC, liver cirrhosis; m, male; MDS, myelodysplastic syndrome; METS, metabolic syndrome; MN, malnutrition; NA, not applicable; NF1, neurofibromatosis type 1; NSCLC, non-small cell lung cancer; PH, pulmonary hypertension; RA, rheumatoid arthritis, RI, renal insufficiency; S, sarcoidosis; SMF, secondary myelofibrosis; T2DM, type 2 diabetes mellitus; VOC, variant of concern.

In order to depict the cell types, which were infected by SARS-CoV-2, dual RNA-ISH were performed. Intracellular SARS-CoV-2 signals in lung tissue was significantly less in patients with known T2DM (p = 0.01).
molecule (CD68; median 17 positive cells/mm², range 10–29) RNA expressing alveolar macrophages (Fig. 1 I). A SARS-CoV-2 RNA signal was significantly less frequently detected in Melanoma Cell Adhesion Molecule (MCAM) RNA-positive endothelial cells (Fig. 1 H). In these cases, only isolated viral transcripts could be detected even in cases with high viral load (median 1 positive cells/mm², range 0–1; Fig. 2 D). In addition, viral RNA was present in hyaline membranes covering the alveolar spaces in 11 cases (Fig. 1 D).

4. Discussion

The interaction of the viral Spike protein with cellular receptors (e.g. ACE2, TMPRSS2, and others) allows SARS-CoV-2 to efficiently enter its target cells [17,27]. These receptors are not only present on lung epithelial cells, but have also been reported to be consistently expressed on endothelial cells [10].

In line with the high expression of SARS-CoV-2 receptors in lung epithelial cells, SARS-CoV-2 Spike protein coding RNA was detected in KRT18 RNA expressing lung epithelial cells. As viral RNA is generated during viral replication in infected cells, the presence of viral RNA in hyaline membranes may be explained by death or lysis of infected epithelial cells. SARS-CoV-2 infection has been shown to exert variable cytopathogenic effects, ranging from lysis of the infected cells to no cytopathic effect in spite of intense viral replication [29]. This is in line with electron microscopy observations showing that new SARS-CoV-2 particles were expelled from the cells, through cell lysis or by fusion of virus containing vacuoles with the cell plasma membrane [3]. Alternatively, release of viral RNA may be related to the hosts immune cells attacking infected cells. However, viral particles present in the alveolar spaces will be included during aerosol and droplet generation and will thus be shed by patients with active viral replication during breathing and talking [5] suggesting that detectable viral RNA in the alveolar spaces may also be considered as a surrogate of patients infectivity. However, we cannot reliably determine the source of the viral RNA detected extracellularly in the hyaline membranes. Besides direct viral infection a concurrent explanation for the presence of viral RNA in alveolar macrophages (expressing CD68 RNA) could be phagocytosis of alveolar debris.

As autopsy studies revealed focal capillary microthrombosis and vascular dysfunction as the most likely factor leading to alveolar damage and consequently lung fibrosis during SARS-CoV-2 lung infection [13, 18], the observation that endothelial cells also express SARS-CoV-2
receptors could be of special interest [10]. Noteworthy, initial reports demonstrated SARS-CoV-2 viral particles in renal but not lung endothelial cells [18,26], while others suggested a misinterpretation of autolytically altered cellular organelles as viral particles [9]. We were not able to reliably detect viral particles by electron microscopy in lung endothelial cells using tissues retrieved from autopsies of COVID-19 patients (data not shown). Similarly, Cortese et al. were not able to detect SARS-CoV-2 in lung endothelial cells and Stahl et al. did not find SARS-CoV-2 infected endothelial cells in the gut [7,24]. Thus, we decided for an alternate diagnostic approach allowing for the analysis of larger tissue areas. Indeed, we were able to identify single virus-positive endothelial cells using dual RNA in situ hybridization in cases with high viral load (Fig. 1H), but the vast majority of the examined cases were negative for SARS-CoV-2 RNA in lung endothelial cells. As COVID-19-related lung damage was histologically present in nearly all of our patients (n = 38/40), it seems unlikely that direct viral infection of lung endothelial cells is key for the induction of capillary microthrombosis. In line with this finding, platelets have been shown to express both ACE2 and TMPRSS2 and the viral Spike protein was able to directly enhance platelet activation [33] suggesting that altered platelet function itself might be involved in the pathogenesis of thrombotic events during COVID-19.

Other striking findings in lungs of deceased COVID-19 patients include morphological changes affecting type II pneumocytes like hyperplasia, multinucleation, and squamous metaplasia besides accumulation of alveolar macrophages [4,13,31]. Here, we demonstrated the presence of SARS-CoV-2 RNA in lung epithelial cells and alveolar macrophages. Interestingly, spatial transcriptomics suggested that squamous metaplasia may be an important feature of SARS-CoV-2 pneumonia and revealed that SARS-CoV-2 infection may increase epithelial-to-mesenchymal transition besides activation of extracellular matrix pathways [16]. These transcriptomic analyses also pointed to the direction that SARS-CoV-2 macrophages are alternatively activated and may contribute to tissue remodeling during COVID-19 pneumonia. Taken together, these findings suggest that the infection of lung epithelial cells may directly affect the function of the air-blood barrier and may together with virus containing alveolar macrophages contribute to progressive lung fibrosis in patients with severe COVID-19 [31].

The duration of infectivity of SARS-CoV-2 infected people has major implications for public health and duration of quarantine measures used for pandemic control. Viral RNA is detectable in nasopharyngeal swabs 2–3 days before onset of symptoms at which viral titers peak, and decline over the following 7–8 days in most patients [11,25,28]. However, there are some patients in which viral RNA can be detected for weeks and months [20,23,32], which cannot be considered as a general surrogate of infectivity [22]. Similar results have been reported from animal models [2,21]. Initially, the duration of viral shedding and thus the contagious period of SARS-CoV-2 infected patients has been reported to last about three weeks [19,30], but vaccination has shown to reduce the time to viral clearance [6]. Here, we observed a steady decrease in SARS-CoV-2 Spike protein-coding RNA signals in lung tissue over a period of three weeks, which is similar to the data provided by Desai et al. [8] and consistent with the reported periods of viral shedding in a non-vaccinated population. Interestingly, high and persistent SARS-CoV-2 shedding in the lower respiratory tract has been associated with a severe course of COVID-19 [5], which was the case in most of our patients. Noteworthy, we did not observe a significant difference in viral

Fig. 2. Quantification of viral RNA in lung tissue A) Clearance of viral RNA from lung tissue over time. B) Comparison of SARS-CoV-2 RNA signals in deceased COVID-19 patients with and without prior anti-SARS-CoV-2 vaccination. C) Viral RNA signals in different stages of COVID-19 pneumonia. D) Quantification of viral RNA in different cell types. CD68 marks alveolar macrophages. KRT 18 was used to detect lung epithelial cells and MCAM was used to identify SARS-CoV-2 in endothelial cells. *p < 0.05; **p < 0.01; ns, not significant.
load between vaccinated and non-vaccinated patients with fatal COVID-19 (p > 0.05). Whether this may be attributable to the low number of deceased vaccinated COVID-19 patients in our cohort or related to the fact of disease fatality remains a subject for future analysis.

5. Conclusions

We characterized the natural course of viral clearance of SARS-CoV-2 RNA in lung tissue of adults with severe COVID-19 and fatal outcome. Furthermore, we demonstrated that variants of concern can be detected using the described RNA in situ hybridization approach. Our observations indicate that pulmonary microthrombosis, a known driver of disease progression, is likely not a direct consequence of endothelial cells infection.

CRediT authorship contribution statement

Constantin Schwab: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft. Lisa Maria Domke: Data curation, Funding acquisition, Project administration, Review and editing draft. Fabian Rose: Formal analysis, Investigation, Methodology, Review and editing draft. Ingrid Hausser: Investigation, Methodology, Review and editing draft. Peter Schirmacher: Funding acquisition, Supervision, Review and editing draft. Thomas Longerich: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Review and editing draft.

Funding

The study was funded by the Ministry of Science, Research and Art of Baden-Wuerttemberg (Baden-Wuerttemberg Corona Autopsy Biobank and Registry and “Sonderfördermaßnahme COVID-19 Forschung”, HD14 to TL).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank Martin Bär and his team for supporting the COVID-19 autopsies and the biobank of the German Center for Infection Research (Deutsches Zentrum für Infekionsforschung, DZIF) for the procurement and administration of tissue samples

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.prp.2022.154000.

References

[1] M. Ackermann, S.E. Verleden, M. Kuehnel, A. Haverich, T. Welte, F. Laenger, A. Vanstapel, C. Werlein, H. Stark, A. Tzankov, W.W. Li, J.P. Bauduin, G. Haddad, M. Le Bideau, J. Pfeifer, C.C. Midkiff, P. van Run, L. Leijten, R. Sikkema, E. Verschoor, B. Verstrepen, W. Bogers, D. Jonigk, P. Schirmacher, T. Longerich, The pathology of severe COVID-19-related lung damage, Dtsch. Arzteblatt Int. 117 (2020) 500–506.

[2] F. Liu, K. Han, R. Blair, K. Kenz, Z. Qin, B. Upcin, P. Wortsdorfer, C.C. Midkiff, J. Mudd, B. Elyasneva, N.S. Milligan, T.D. Rorison, N. Wagner, J. Bomden, R.H. Axts, R.S. Vander Heide, X.M. Yin, J.K. Kols, C.J. Roy, J. Rappaport, S. Ergin, X. Qin, SARS-CoV-2 infects endothelial cells in vivo and in vitro, Front. Cell. Infect. Microbiol. 11 (2021) 701728.

[3] J. Liu, Y. Li, Q. Liu, Q. Yao, X. Wang, H. Zhang, R. Chen, L. Ren, J. Min, F. Deng, B. Yan, L. Liu, Z. Hu, M. Wang, Y. Zhou, SARS-CoV-2 cell tropism and multisegment infection, Cell Discov. 7 (2021) 17.

[4] C. Margaroli, P. Benson, N.S. Sharma, M.C. Madison, S.W. Robinson, N. Arora, K. Ton, Y. Liang, L. Zhang, R.P. Patel, A. Gaggero, Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies differential transcriptional signatures, Cell Rep. Med. 2 (2021), 100242.

[5] S. Matsuyama, N. Nao, K. Shirotaro, M. Kawase, S. Saito, I. Takayama, N. Nagata, T. Sekizuka, H. Kato, F. Kato, M. Sakata, M. Tahara, K. Katsuna, N. Ohmagari, M. Kuroda, T. Suzuki, T. Kageyama, T. Takeda, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc. Natl. Acad. Sci. USA 117 (2020) 7001–7003.

[6] T. Menter, J.D. Hadlauer, R. Nienhold, S. Savic, H. Hopfer, N. Deignendesch, S. Frank, H. Park, N. Willi, I. Peri, F. Gubler, R. Lipter, L. Vences, M. Tolnay, K.D. Mertz, A. Tzankov, Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction, Histopathology 177 (2020) 198–209.

[7] Y. Miyamae, T. Hayashi, H. Yoneyzawa, J. Fujihara, M. Yamamoto, T. Totsuka, K. Ishii, Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: a single-hospital experience in Tokyo, Japan, Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 97 (2020) 293–295.

[8] S.Y. Park, S.G. Yun, J.W. Shin, B.Y. Lee, H.J. Son, S. Lee, E. T.H. Kim, Persistent severe acute respiratory syndrome coronavirus 2 detection after resolution of coronavirus disease 2019-associated symptoms/signs, Korean J. Intern. Med. 35 (2020) 793–796.

[9] B. Rocks, T. Kuiken, S. Herfst, T. Bestebroer, M.M. Lamers, B.B. Oude Munnink, D. de Medeiros, G. van Amerongen, J. van den Brand, N.M.A. Okba, D. Schipper, P. van Heusden, L. Leijten, R. Sikkema, E. Verschoor, B. Verstrepen, W. Bogers, M. Koopmans, B.L. Haagmans, Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model, Science 368 (2020) 1012–1015.
K.Y. Yuen, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect. Dis. 20 (2020) 565–574.

Z. Varga, A.J. Flammer, P. Steiger, M. Haberekker, R. Andermann, A.S. Zinkernagel, M.R. Mehra, R.A. Schuepbach, F. Ruschitzka, H. Moch, Endothelial cell infection and endotheliitis in COVID-19, Lancet 395 (2020) 1417–1418.

Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, G. Qiao, Y. Hu, K. Y. Yuen, Q. Wang, H. Zhou, J. Yan, J. Qi, Structural and functional basis of SARS-CoV-2 entry by using human ACE2, Cell 181 (2020) 894–904, e899.

R. Wölfel, V.M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M.A. Müller, D. Niemeyer, T.C. Jones, P. Vollmar, C. Rothe, M. Holscher, T. Bleicker, S. Brünink, J. Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner, Virological assessment of hospitalized patients with COVID-19, Nature 581 (2020) 465–469.

N. Wurtz, G. Penant, P. Jardot, N. Duclos, B. La Scola, Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile, Eur. J. Clin. Microbiol. Infect. Dis. 40 (2021) 477–484.

A.T. Xiao, Y.X. Tong, C. Gao, L. Zhu, Y.J. Zhang, S. Zhang, Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study, J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 127 (2020), 104346.

X.H. Yao, T. Luo, Y. Shi, Z.C. He, R. Tang, P.P. Zhang, J. Cai, X.D. Zhou, D.P. Jiang, X.C. Fei, X.Q. Huang, L. Zhao, H. Zhang, H.B. Wu, Y. Ren, Z.H. Liu, H.R. Zhang, C. Chen, W.J. Fu, H. Li, X.Y. Xia, R. Chen, Y. Wang, X.D. Liu, C.L. Yin, Z.X. Yan, J. Wang, R. Jing, T.S. Li, W.Q. Li, C.F. Wang, Y.Q. Ding, Q. Mao, D.Y. Zhang, S. Zhang, Y.F. Ping, X.W. Bian, A cohort autopsy study defines COVID-19 systemic pathogenesis, Cell Res. 31 (2021) 836–846.

F. Yu, L. Yan, N. Wang, S. Yang, L. Wang, Y. Tang, G. Gao, S. Wang, C. Ma, R. Xie, F. Wang, C. Tan, L. Zhu, Y. Guo, F. Zhang, Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 71 (2020) 793–798.

S. Zhang, Y. Liu, X. Wang, L. Yang, H. Li, Y. Wang, M. Liu, X. Zhao, Y. Xie, Y. Yang, S. Zhang, Z. Fan, J. Dong, Z. Yuan, Z. Ding, Y. Zhang, L. Hu, SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19, J. Hematol. Oncol. 13 (2020) 120.